Clinical Trial Update: Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial update on using celecoxib to prevent progression to multiple myeloma in patients with MGUS or smoldering myeloma; the study is completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-06-09